APA (7th ed.) Citation

GC, S., J, C., C, H., K, R., M, S., P, H., & L, R. (2014). Tumor-infiltrating lymphocyte therapy for melanoma: Rationale and issues for further clinical development. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 28(5), 421. https://doi.org/10.1007/s40259-014-0097-y

Chicago Style (17th ed.) Citation

GC, Sim, Chacon J, Haymaker C, Ritthipichai K, Singh M, Hwu P, and Radvanyi L. "Tumor-infiltrating Lymphocyte Therapy for Melanoma: Rationale and Issues for Further Clinical Development." BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 28, no. 5 (2014): 421. https://doi.org/10.1007/s40259-014-0097-y.

MLA (9th ed.) Citation

GC, Sim, et al. "Tumor-infiltrating Lymphocyte Therapy for Melanoma: Rationale and Issues for Further Clinical Development." BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy, vol. 28, no. 5, 2014, p. 421, https://doi.org/10.1007/s40259-014-0097-y.